Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.

The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.

Inclusion Criteria:

• Patient with Multiple Sclerosis Relapsing-Remitting form
• Patient with cognitive impairment (as spontaneous complaint by either patient or family)
• Patient treated with interferon and maintaining same dosage for previous 6 months
• Patient without major disability (Kurtzke Extended Disability Status Scale ≤6)

Exclusion Criteria:

• Clinical Multiple Sclerosis relapse within 3 months prior to participation
• Major psychiatric disease according to Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.
• Other concomitant disorders possibly jeopardizing the cognitive status evaluation or the follow up of the patient (severe impairment of visual or motor function which may prevent participation in neuropsychological testing)